Showing 1 - 7 results of 7 for search 'Michael Man', query time: 0.04s Refine Results
  1. 1
    Applications of C₂-symmetric bis(azaferrocenes) in asymmetric copper-catalyzed reactions

    Applications of C₂-symmetric bis(azaferrocenes) in asymmetric copper-catalyzed reactions by Lo, Michael Man-chu, 1971-

    Published 2005
    Get full text
    Thesis
  2. 2
    Bioprosthetic Aortic Valve Replacement in <50 Years Old Patients – Where is the Evidence?

    Bioprosthetic Aortic Valve Replacement in <50 Years Old Patients – Where is the Evidence? by Amer Harky, Michael Man Yuen Suen, Chris Ho Ming Wong, Abdul Rahman Maaliki, Mohamad Bashir

    Published 2019-05-01
    Get full text
    Article
  3. 3
    Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.

    Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. by Gianluigi Giannelli, Armando Santoro, Robin K Kelley, Ed Gane, Valerie Paradis, Ann Cleverly, Claire Smith, Shawn T Estrem, Michael Man, Shuaicheng Wang, Michael M Lahn, Eric Raymond, Karim A Benhadji, Sandrine Faivre

    Published 2021-01-01
    Get full text
    Article
  4. 4
    Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.

    Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. by Gianluigi Giannelli, Armando Santoro, Robin K Kelley, Ed Gane, Valerie Paradis, Ann Cleverly, Claire Smith, Shawn T Estrem, Michael Man, Shuaicheng Wang, Michael M Lahn, Eric Raymond, Karim A Benhadji, Sandrine Faivre

    Published 2020-01-01
    Get full text
    Article
  5. 5
    Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

    Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer by Antoine Hollebecque, Rocio Garcia-Carbonero, Do-Youn Oh, Emiliano Calvo, Davide Melisi, Teresa Macarulla, Valeria Merz, Erkut Borazanci, Anna Varghese, Camilla Zecchetto, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Shawn T Estrem, Karim A Benhadji, Emin Avsar, Susan C Guba

    Published 2021-03-01
    Get full text
    Article
  6. 6
    A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

    A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer by Ernest Nadal, Mansoor Saleh, Santiago Ponce Aix, Maria Ochoa-de-Olza, Sandip Pravin Patel, Scott Antonia, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Shawn T. Estrem, Jiangang Liu, Emin Avsar, Wen Hong Lin, Karim A. Benhadji, Leena Gandhi, Susan C. Guba, Inmaculada Ales Diaz

    Published 2023-07-01
    Get full text
    Article
  7. 7
    Discovery and Clinical Evaluation of MK‐8150, A Novel Nitric Oxide Donor With a Unique Mechanism of Nitric Oxide Release

    Discovery and Clinical Evaluation of MK‐8150, A Novel Nitric Oxide Donor With a Unique Mechanism of Nitric Oxide Release by Clayton D. Knox, Pieter‐Jan deKam, Karim Azer, Peggy Wong, Antwan G. Ederveen, Diane Shevell, Christopher Morabito, Alan G. Meehan, Wen Liu, Tom Reynders, Jean Francois Denef, Anna Mitselos, Daniel Jonathan, David E. Gutstein, Kaushik Mitra, Shu Yu Sun, Michael Man‐Chu Lo, Doris Cully, Amjad Ali

    Published 2016-09-01
    Get full text
    Article

Search Tools: